Evolution Group Company News

Epic Code:
Sub Sector:
Market Cap:

General Financial
Investment Services
UK Main Market
335.59145484 GBPm

Data as of 10:00 23/09/2009. Check director details and other company announcments at Evolution Group Website .

RNS News for Evolution Group

Regulatory News Service : RNS provides a service that enables local or international listed companies to meet company news reporting obligations in UK, Europe and US - international filings use different processes: Provides investors & professionals equal access to new company information as it is released. For further details of RNS news see London Stock Exchange website.

Latest Evolution Group News

Evgen Pharma PLC (EVG) Given Buy Rating at Northland Securities
The Cerbat Gem - 2 hours ago
Evgen Pharma PLC logo Northland Securities reaffirmed their buy rating on shares of Evgen Pharma PLC (LON:EVG) in a research report sent to investors on Thursday, June 1st.

06/25/2017 01:56 AM

Evgen Pharma Plc Making clinical progress
DirectorsTalk Interviews - Jun 21, 2017
Hardman & Co Report Report Downloads Evgen Pharma Plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways involved ...
Evgen Pharma PLC (EVG) Receives Buy Rating from Northland Securities - Chaffey Breeze

06/21/2017 07:33 AM

Market Risers: Evgen Pharma PLC, Fresnillo Plc, Hammerson plc, Lionsgold Ltd
DirectorsTalk Interviews - Jun 14, 2017
Shares in Evgen Pharma PLC with ticker code: LON:EVG has gained 5.66% or 0.99 points during today's session so far. Buyers have remained optimistic during this period.

06/14/2017 01:00 PM

Evgen Pharma PLC Q&A with Chief Executive Officer Dr Stephen Franklin (LON:EVG)
DirectorsTalk Interviews - Jun 14, 2017
Evgen Pharma is a capital-efficient clinical stage drug company and we're focussed on the development of novel medicines based upon a molecule called sulforaphane.

06/14/2017 11:52 AM

Evgen Pharma plc SFX-01 product candidate now into two phase II clinical trials
DirectorsTalk Interviews - Jun 13, 2017
Dr Stephen Franklin, Chief Executive Officer of Evgen Pharma plc, said: “We are very pleased to have progressed our SFX-01 product candidate into two phase II clinical trials: in breast cancer and in subarachnoid haemorrhage.

06/13/2017 07:22 AM

Evgen Pharma shares jump after positive updates on two Phase II clinical ...
Proactive Investors UK - Jun 1, 2017
Evgen Pharma PLC (LON:EVG) saw its shares jump almost 12% higher this morning after the drug development company reported positive updates on two Phase II clinical trials for its SFX-01 treatment with “no safety or tolerance issues reported to date”.
Evgen Pharma PLC Compassionate Use Programme and Trials Update - DirectorsTalk Interviews

06/01/2017 10:33 AM